

ENSEIGNEMENT & PUBLICATIONS

CHIRURGIE UROLOGIQUE

Le Département d'Urologie est très impliqué dans les activités académiques, tant au plan national qu'au niveau international.

Enseignement universitaire

Le Département d'Urologie de l'Institut Mutualiste Montsouris est affilié à l'Université de Paris (ex Université Paris Descartes) :

Accueil, chaque trimestre, d'étudiants en 5^{ème} année de médecine.

Accueil, chaque semestre, d'internes en urologie de Paris (APHP) et d'autres hôpitaux universitaires français (inter-CHU)

Participation à de multiples enseignements universitaires

Le Département a également développé des relations académiques étroites avec de nombreux hôpitaux universitaires internationaux (sur les cinq continents, notamment Amériques, Asie et Europe)

Accueil, chaque semestre, de chirurgiens urologues venant perfectionner leurs connaissances, notamment dans les technologies innovantes et la cancérologie en Urologie.

Partenariat permanent pour travaux de recherche et publications (cf publications)

Recherche et publication

Le Département d'Urologie contribue activement à de nombreux travaux de recherche, **au sein de l'IMM et en lien avec des institutions référentes, nationales (INSERM, Institut Curie,...) et internationales (notamment aux USA, Amérique latine et en Europe).**

Cette recherche académique s'inscrit dans le cadre de multiples protocoles dont le département est investigateur voire promoteur (> 25 en cours) , à la source de nombreuses publications référencées (>25 / an en moyenne, > 90 % internationales).

2020

The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series.

Stabile A, Orczyk C, Giganti F, Moschini M, Allen C, Punwani S, Cathala N, Ahmed HU, Cathelineau X, Montorsi F, Emberton M, Briganti A, Sanchez-Salas R, Moore CM. Stabile A, et al. Eur Urol.

2020 May 19;S0302-2838(20)30336-5. doi: 10.1016/j.eururo.2020.04.068. Online ahead of print. Eur Urol. 2020. PMID: 32444261

Re: MRI-Targeted, Systematic, and Combined Biopsy for Prostate Cancer Diagnosis.

Rodríguez Sánchez L, Macek P, Barbé Y, Cathelineau X, Sanchez-Salas R. Rodríguez Sánchez L, et al. Eur Urol.

2020 May 6;S0302-2838(20)30254-2. doi: 10.1016/j.eururo.2020.04.022. Online ahead of print. Eur Urol. 2020. PMID: 32387122 No abstract available.

Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial.

Afferi L, Moschini M, Mattei A, Montorsi F, Briganti A, Cathelineau X, Sanchez-Salas R. Afferi L, et al. Eur Urol.

2020 Apr 28;S0302-2838(20)30238-4. doi: 10.1016/j.eururo.2020.04.006. Online ahead of print. Eur Urol. 2020. PMID: 32359702 No abstract available.

Re: Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.

Marra G, Moschini M, Cathelineau X, Sanchez-Salas R. Marra G, et al. *J Urol*. 2020 Mar 6;101097JU00000000000001008. doi: 10.1097/JU.0000000000001008. Online ahead of print. *J Urol*. 2020. PMID: 32141803 No abstract available.

Reply by Authors.

Claros OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, Muttin F, Carneiro A, Stabile A, Moschini M, Macek P, Cathala N, Mombet A, Sanchez-Salas R, Cathelineau X. Claros OR, et al. *J Urol*. 2020 May;203(5):924-925. doi: 10.1097/JU.0000000000000692.03. Epub 2020 Feb 20. *J Urol*. 2020. PMID: 32077801 No abstract available.

Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.

Claros OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, Muttin F, Carneiro A, Stabile A, Moschini M, Macek P, Cathala N, Mombet A, Sanchez-Salas R, Cathelineau X. Claros OR, et al. *J Urol*. 2020 May;203(5):918-925. doi: 10.1097/JU.0000000000000692. Epub 2019 Dec 10. *J Urol*. 2020. PMID: 31821099

Reply by Authors.

Tourinho-Barbosa RR, Sanchez-Salas R, Claros OR, Collura-Merlier S, Bakavicius A, Carneiro A, Stabile A, Moschini M, Cathala N, Tobias-Machado M, Cathelineau X. Tourinho-Barbosa RR, et al. *J Urol*. 2020 Feb;203(2):329-330. doi: 10.1097/01.JU.0000614908.52884.48. Epub 2019 Nov 13. *J Urol*. 2020. PMID: 31721682 No abstract available.

Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails.

Moschini M, Shariat SF, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Xylinas E, Roupret M, Boorjian SA, Catto JW, Sanchez-Salas R. Moschini M, et al. *Eur Urol*. 2020 Jan;77(1):1-2. doi: 10.1016/j.eururo.2019.08.021. Epub 2019 Sep 8. *Eur Urol*. 2020. PMID: 31506227

Focal Therapy for Localized Prostate Cancer with Either High Intensity Focused Ultrasound or Cryoablation: A Single Institution Experience.

Tourinho-Barbosa RR, Sanchez-Salas R, Claros OR, Collura-Merlier S, Bakavicius A, Carneiro A, Stabile A, Moschini M, Cathala N, Tobias-Machado M, Cathelineau

X.Tourinho-Barbosa RR, et al.J Urol.

2020 Feb;203(2):320-330. doi: 10.1097/JU.0000000000000506. Epub 2019 Aug 22.J Urol. 2020.PMID: 31437121

Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience.

Saad M, Moschini M, Stabile A, Macek P, Lanz C, Prapotnich D, Rozet F, Cathala N, Mombet A, Sanchez-Salas R, Cathelineau X.Saad M, et al.BJU Int.

2020 Feb;125(2):253-259. doi: 10.1111/bju.14850. Epub 2019 Jul 12.BJU Int. 2020.PMID: 31220396

2019

The importance of antiandrogen in prostate cancer treatment.

Lanz C, Bennamoun M, Macek P, Cathelineau X, Sanchez-Salas R.Lanz C, et al. Ann Transl Med. 2019 Dec;7(Suppl 8):S362. doi: 10.21037/atm.2019.09.53. Ann Transl Med.

2019.PMID: 32016080 Free PMC article. No abstract available.

Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro-Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer.

Claros OR, Tourinho-Barbosa RR, Fregeville A, Gallardo AC, Muttin F, Carneiro A, Stabile A, Moschini M, Macek P, Cathala N, Mombet A, Sanchez-Salas R, Cathelineau X. Claros OR, et al. J Urol.

2020 May;203(5):918-925. doi: 10.1097/JU.0000000000000692. Epub 2019 Dec 10. J Urol. 2020.PMID: 31821099

HRQOL related to urinary diversion in Radical Cystectomy: a systematic review of recent literature.

Pazeto CL, Baccaglioni W, Tourinho-Barbosa RR, Glina S, Cathelineau X, Sanchez-Salas R. Pazeto CL, et al. Int Braz J Urol.

2019 Nov-Dec;45(6):1094-1104. doi: 10.1590/S1677-5538.IBJU.2018.0858. Int Braz J Urol. 2019.PMID: 31808396 Review.

Reply by Authors.

Tourinho-Barbosa RR, Sanchez-Salas R, Claros OR, Collura-Merlier S, Bakavicius A, Carneiro A, Stabile A, Moschini M, Cathala N, Tobias-Machado M, Cathelineau X. Tourinho-Barbosa RR, et al. J Urol.

2020 Feb;203(2):329-330. doi: 10.1097/01.JU.0000614908.52884.48. Epub 2019 Nov 13. J Urol. 2020.PMID: 31721682 No abstract available.

Focal therapy for prostate cancer - index lesion treatment vs. hemiablation. A matter of definition.

Stabile A, Moschini M, Montorsi F, Cathelineau X, Sanchez-Salas R. Stabile A, et al. *Int Braz J Urol.*

2019 Sep-Oct;45(5):873-876. doi: 10.1590/S1677-5538.IBJU.2019.05.02. *Int Braz J Urol.* 2019. PMID: 31626515 Free PMC article. No abstract available.

HIFU focal therapy for prostate cancer using intraoperative contrast enhanced ultrasound.

Claros OR, Tourinho-Barbosa RR, Carneiro A, Collura-Merlier S, Macek P, Lanz C, Cathala N, Prapotnich D, Mombet A, Sanchez-Salas R, Cathelineau X. Claros OR, et al. *Arch Esp Urol.*

2019 Oct;72(8):825-830. *Arch Esp Urol.* 2019. PMID: 31579041 English.

Multimodal treatment in focal therapy for localized prostate cancer using concomitant short-term androgen deprivation therapy: the ENHANCE prospective pilot study.

Marra G, Dell'oglio P, Baghdadi M, Cathelineau X, Sanchez-Salas R; Evaluation of HIFU Hemiablation and short-term Androgen deprivation therapy Combination to Enhance prostate cancer control (ENHANCE) Study. Marra G, et al. *Minerva Urol Nefrol.*

2019 Oct;71(5):544-548. doi: 10.23736/S0393-2249.19.03599-9. Epub 2019 Sep 6. *Minerva Urol Nefrol.* 2019. PMID: 31508924

Do Not Learn a Technique, Learn the Biology Underlying the Disease: Techniques Evolve, Biology Prevails.

Moschini M, Shariat SF, Black P, Kamat AM, Stabile A, Cathelineau X, Kassouf W, Bochner BH, Xylinas E, Roupret M, Boorjian SA, Catto JW, Sanchez-Salas R. Moschini M, et al. *Eur Urol.*

2020 Jan;77(1):1-2. doi: 10.1016/j.eururo.2019.08.021. Epub 2019 Sep 8. *Eur Urol.* 2020. PMID: 31506227

Focal Therapy for Localized Prostate Cancer with Either High Intensity Focused Ultrasound or Cryoablation: A Single Institution Experience.

Tourinho-Barbosa RR, Sanchez-Salas R, Claros OR, Collura-Merlier S, Bakavicius A, Carneiro A, Stabile A, Moschini M, Cathala N, Tobias-Machado M, Cathelineau X. Tourinho-Barbosa RR, et al. *J Urol.*

2020 Feb;203(2):320-330. doi: 10.1097/JU.0000000000000506. Epub 2019 Aug 22. *J Urol.* 2020. PMID: 31437121

Enhanced recovery after surgery (ERAS) in radical cystectomy patients: from

consensus to evidences.

Moschini M, Stabile A, Mattei A, Montorsi F, Cathelineau X, Sanchez-Salas R. Moschini M, et al. *Int Braz J Urol.*

2019 Jul-Aug;45(4):655-657. doi: 10.1590/S1677-5538.IBJU.2019.04.02.Int Braz J Urol. 2019. PMID: 31397986 Free PMC article. No abstract available.

Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes.

Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan WS, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz PI, Rouprêt M, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Lotan Y, Sooriakumaran P, Shariat SF. Moschini M, et al. *J Clin Med.* 2019 Aug 9;8(8):1192. doi: 10.3390/jcm8081192. *J Clin Med.*

2019. PMID: 31395826 Free PMC article.

Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?

Gómez Rivas J, Carrion DM, Alvarez-Maestro M, Cathelineau X, Sanchez-Salas R, Di Lorenzo G, Di Maio M, Paul A, Martinez-Piñeiro L, Sartor O, Saad F, Debruyne F. Gómez Rivas J, et al. *Minerva Urol Nefrol.*

2019 Oct;71(5):445-456. doi: 10.23736/S0393-2249.19.03420-9. Epub 2019 Jul 25. *Minerva Urol Nefrol.* 2019. PMID: 31353876 Review.

13.

Long-term functional and oncological outcomes of nerve-sparing and prostate capsule-sparing cystectomy: a single-centre experience.

Saad M, Moschini M, Stabile A, Macek P, Lanz C, Prapotnich D, Rozet F, Cathala N, Mombet A, Sanchez-Salas R, Cathelineau X. Saad M, et al. *BJU Int.*

2020 Feb;125(2):253-259. doi: 10.1111/bju.14850. Epub 2019 Jul 12. *BJU Int.* 2020. PMID: 31220396

Tumor Cells Hijack Macrophage-Produced Complement C1q to Promote Tumor Growth.

Roumenina LT, Daugan MV, Noé R, Petitprez F, Vano YA, Sanchez-Salas R, Becht E, Meilleroux J, Clec'h BL, Giraldo NA, Merle NS, Sun CM, Verkarre V, Validire P, Selves J, Lacroix L, Delfour O, Vandenberghe I, Thuilliez C, Keddani S, Sakhi IB, Barret E, Ferré P, Corvaia N, Passiukov A, Chetaille E, Botto M, de Reynies A, Oudard SM, Mejean A, Cathelineau X, Sautès-Fridman C, Fridman WH. Roumenina LT, et al. *Cancer Immunol*

Res.

2019 Jul;7(7):1091-1105. doi: 10.1158/2326-6066.CIR-18-0891. Epub 2019 Jun 4. *Cancer Immunol Res.* 2019. PMID: 31164356

Comprehensive Evaluation of Focal Therapy Complications in Prostate Cancer: A Standardized Methodology.

Bakavicius A, Sanchez-Salas R, Muttin F, Sivaraman A, Dell'Oglio P, Barret E, Rozet F, Mombet A, Prapotnich D, Cathala N, Cathelineau X. Bakavicius A, et al. *J Endourol.* 2019 Jul;33(7):509-515. doi: 10.1089/end.2018.0809. Epub 2019 May 31. *J Endourol.* 2019. PMID: 31017001

Biochemical recurrence-free conditional probability after radical prostatectomy: A dynamic prognosis.

García-Barreras S, Sanchez-Salas R, Mejia-Monasterio C, Muttin F, Secin F, Dell'Oglio P, Nunes-Silva I, Srougi V, Barret E, Rozet F, Prapotnich D, Cathelineau X. García-Barreras S, et al. *Int J Urol.* 2019 Jul;26(7):725-730. doi: 10.1111/iju.13982. Epub 2019 Apr 18. *Int J Urol.* 2019. PMID: 31001870

Re: Radical Prostatectomy or Watchful Waiting in Prostate Cancer-29-Year Follow-up.

Cathelineau X, Macek P, Sanchez-Salas R. Cathelineau X, et al. *Eur Urol.* 2019 Jul;76(1):130-131. doi: 10.1016/j.eururo.2019.03.033. Epub 2019 Apr 5. *Eur Urol.* 2019. PMID: 30955972 No abstract available.

Robotic-assisted radical prostatectomy: The teaching.

Martínez-Alonso IA, Valdez-Flores RA, Padrón-Lucio S, Campos Salcedo JG, Gutierrez-Aceves J, Cathelineau X, Sánchez-Salas R. Martínez-Alonso IA, et al. *Arch Esp Urol.* 2019 Apr;72(3):239-246. *Arch Esp Urol.* 2019. PMID: 30945650 English, Spanish.

Immediate versus delayed prostatectomy and the fate of patients who progress to a higher risk disease on active surveillance.

Mallya A, Senguttuvan-Karthikeyan V, Sivaraman A, Barret E, Galiano M, Cathala N, Mombet A, Prapotnich D, Sanchez-Salas R, Cathelineau X. Mallya A, et al. *Actas Urol Esp.* 2019 Jul-Aug;43(6):324-330. doi: 10.1016/j.acuro.2018.04.005. Epub 2019 Mar 28. *Actas Urol Esp.* 2019. PMID: 30928176 English, Spanish.

Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence.

Marconi L, Stonier T, Tourinho-Barbosa R, Moore C, Ahmed HU, Cathelineau X,

Emberton M, Sanchez-Salas R, Cathcart P, Marconi L, et al. *Eur Urol*. 2019 Jul;76(1):27-30. doi: 10.1016/j.eururo.2019.03.007. Epub 2019 Mar 21. *Eur Urol*. 2019. PMID: 30904357

Oncological outcomes and pathological characteristics of cT1 upstaging to pT3a renal cell carcinoma compared with de novo pT3a tumors.

Senguttuvan Karthikeyan V, Mallya A, Sivaraman A, Galiano M, Rozet F, Cathala N, Barret E, Mombet A, Prapotnich D, Sanchez-Salas R, Cathelineau X, Senguttuvan Karthikeyan V, et al. *Actas Urol Esp*. 2019 Jun;43(5):234-240. doi: 10.1016/j.acuro.2018.03.008. Epub 2019 Mar 8. *Actas Urol Esp*. 2019. PMID: 30857765 English, Spanish.

Screening: Actual trends on PSA marker. When, who, how?

Baccaglini W, Cathelineau X, Araújo G, Medina LG, Sotelo R, Carneiro A, Sanchez-Salas R, Baccaglini W, et al. *Arch Esp Urol*. 2019 Mar;72(2):98-103. *Arch Esp Urol*. 2019. PMID: 30855010 English.

Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery.

Moschini M, Martini A, Zamboni S, Mattei A, Baumeister P, Di Bona C, Dell'Oglio P, Zaffuto E, Burgio G, Shariat SF, Sanchez-Salas R, Cathelineau X, Salonia A, Montorsi F, Briganti A, Gallina A, Colombo R, Moschini M, et al. *Clin Genitourin Cancer*. 2019 Jun;17(3):e541-e548. doi: 10.1016/j.clgc.2019.02.001. Epub 2019 Feb 13. *Clin Genitourin Cancer*. 2019. PMID: 30850337

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.

Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, Jievaltas M, Luz M, Alekseev B, Kuss I, Kappeler C, Snapir A, Sarapohja T, Smith MR; ARAMIS Investigators. Fizazi K, et al. *N Engl J Med*. 2019 Mar 28;380(13):1235-1246. doi: 10.1056/NEJMoa1815671. Epub 2019 Feb 14. *N Engl J Med*. 2019. PMID: 30763142 Clinical Trial.

Complications, oncological and functional outcomes of salvage treatment options following focal therapy for localized prostate cancer: a systematic review and a comprehensive narrative review.

Marra G, Gontero P, Walz JC, Sivaraman A, Tourinho-Barbosa R, Cathelineau X, Sanchez-Salas R, Marra G, et al. *World J Urol*. 2019 Aug;37(8):1517-1534. doi: 10.1007/s00345-019-02642-9. Epub 2019 Feb 1. *World J Urol*. 2019. PMID: 30710157

Editorial Comment.

Cathelineau X, Sanchez-Salas R. Cathelineau X, et al. *J Urol*.

2019 Jan;201(1):119. doi: 10.1097/01.ju.0000550165.58711.a5. *J Urol*. 2019. PMID: 30577403 No abstract available.

The clinical role of the TME in solid cancer.

Giraldo NA, Sanchez-Salas R, Peske JD, Vano Y, Becht E, Petitprez F, Validire P, Ingels A, Cathelineau X, Fridman WH, Sautès-Fridman C. Giraldo NA, et al. *Br J Cancer*. 2019 Jan;120(1):45-53. doi: 10.1038/s41416-018-0327-z. Epub 2018 Nov 9. *Br J Cancer*. 2019. PMID: 30413828 Free PMC article. Review.

Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.

Neuzillet Y, Raynaud JP, Dreyfus JF, Radulescu C, Rouanne M, Schneider M, Krish S, Rouprêt M, Drouin SJ, Comperat E, Galiano M, Cathelineau X, Validire P, Molinié V, Fiet J, Giton F, Lebret T, Botto H. Neuzillet Y, et al. *Horm Cancer*.

2019 Feb;10(1):36-44. doi: 10.1007/s12672-018-0351-8. Epub 2018 Oct 6. *Horm Cancer*. 2019. PMID: 30293206 Clinical Trial.

Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer.

Fenioux C, Louvet C, Charton E, Rozet F, Ropert S, Prapotnich D, Barret E, Sanchez-Salas R, Mombet A, Cathala N, Joulia ML, Molitor JL, Henriques J, Bonnetain F, Cathelineau X, Bennamoun M. Fenioux C, et al. *BJU Int*.

2019 Feb;123(2):300-306. doi: 10.1111/bju.14511. Epub 2018 Sep 4. *BJU Int*. 2019. PMID: 30099821

Salvage robotic-assisted radical prostatectomy: oncologic and functional outcomes from two high-volume institutions.

Ogaya-Pinies G, Linares-Espinos E, Hernandez-Cardona E, Jenson C, Cathelineau X, Sanchez-Salas R, Patel V. Ogaya-Pinies G, et al. *World J Urol*.

2019 Aug;37(8):1499-1505. doi: 10.1007/s00345-018-2406-4. Epub 2018 Jul 13. *World J Urol*. 2019. PMID: 30006908 Clinical Trial.